Abstract
Aberrant Notch activation is linked to cancer since 1991 when mammalian Notch1 was first identified as part of the translocation t(7;9) in a subset of human T-cell acute lymphoblastic leukemias (T-ALL). Since then oncogenic Notch signaling has been found in many solid and hematopoietic neoplasms. Depending on tumor type Notch interferes with differentiation, proliferation, survival, cell-cycle progression, angiogenesis, and possibly self-renewal. In hematopoietic neoplasms, recent findings indicate an important role of Notch for TALL induction and progression and the pathogenesis of human T- and B-cell-derived lymphomas. Notch signaling has been identified as a potential new therapeutic target in these hematopoietic neoplasms. This review will focus on the most recent findings on Notch signaling in leukemias and lymphomas and its potential role in the maintenance of malignant stem cells.
Keywords: Notch, T-cell acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, multiple myeloma, cancer stem cells
Current Molecular Medicine
Title: Notch Signaling in Leukemias and Lymphomas
Volume: 8 Issue: 1
Author(s): Franziska Jundt, Rolf Schwarzer and Bernd Dorken
Affiliation:
Keywords: Notch, T-cell acute lymphoblastic leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemia, multiple myeloma, cancer stem cells
Abstract: Aberrant Notch activation is linked to cancer since 1991 when mammalian Notch1 was first identified as part of the translocation t(7;9) in a subset of human T-cell acute lymphoblastic leukemias (T-ALL). Since then oncogenic Notch signaling has been found in many solid and hematopoietic neoplasms. Depending on tumor type Notch interferes with differentiation, proliferation, survival, cell-cycle progression, angiogenesis, and possibly self-renewal. In hematopoietic neoplasms, recent findings indicate an important role of Notch for TALL induction and progression and the pathogenesis of human T- and B-cell-derived lymphomas. Notch signaling has been identified as a potential new therapeutic target in these hematopoietic neoplasms. This review will focus on the most recent findings on Notch signaling in leukemias and lymphomas and its potential role in the maintenance of malignant stem cells.
Export Options
About this article
Cite this article as:
Jundt Franziska, Schwarzer Rolf and Dorken Bernd, Notch Signaling in Leukemias and Lymphomas, Current Molecular Medicine 2008; 8 (1) . https://dx.doi.org/10.2174/156652408783565540
DOI https://dx.doi.org/10.2174/156652408783565540 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Subject Index To Volume 5
Anti-Infective Agents in Medicinal Chemistry Drug Combinatorial Therapies for the Treatment of KRAS Mutated Lung Cancers
Current Topics in Medicinal Chemistry Designing Isoform-selective Inhibitors Against Classical HDACs for Effective Anticancer Therapy: Insight and Perspectives from In Silico
Current Drug Targets B Cells: Programmers of CD4 T Cell Responses
Infectious Disorders - Drug Targets Genomic Signatures for Individualized Treatment of Malignant Tumors
Current Drug Discovery Technologies The Urokinase-type Plasminogen Activator and the Generation of Inhibitors of Urokinase Activity and Signaling
Current Pharmaceutical Design Treatment for Cancer Patients with Oral Mucositis: Assessment Based on the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer in International Society of Oral Oncology (MASCC/ISOO) in 2013 and Proposal of Possible Novel Treatment with a Japanese Herbal Medicine
Current Pharmaceutical Design Novel Drugs for Chronic Lymphoid Leukemias: Mechanism of Action and Therapeutic Activity
Current Medicinal Chemistry The Role of Cancer Biomarkers in HIV Infected Hosts
Current Medicinal Chemistry Editorial [Hot Topic: Oncohematology: From Bench to Bedside (Guest Editor: Vincenzo De Feo)]
Mini-Reviews in Medicinal Chemistry The PTEN/PI3K/AKT Signalling Pathway in Cancer, Therapeutic Implications
Current Cancer Drug Targets NF-κB Down–regulation and PARP Cleavage by novel 3-α-butyryloxy-β-boswellic Acid Results in Cancer Cell Specific Apoptosis and in vivo Tumor Regression
Anti-Cancer Agents in Medicinal Chemistry Recent Applications of Birch Reduction in Total Synthesis of Natural Products
Current Organic Chemistry A Dual Role of Cyclin E in Cell Proliferation and Apotosis May Provide a Target for Cancer Therapy
Current Cancer Drug Targets Dynamics of Toll-like Receptors Signaling in Skeletal Muscle Atrophy
Current Medicinal Chemistry Signal Transduction Pathway Regulated by Genistein and its Therapeutic Use
Current Signal Transduction Therapy Editorial: The Real Impact of Target Therapy in Cancer Patients: Between Hope and Reality
Current Cancer Drug Targets LRRC4 Inhibits Glioma Cell Growth and Invasion Through a miR-185- Dependent Pathway
Current Cancer Drug Targets Multiple Sclerosis: Pathogenesis and Treatment
Current Neuropharmacology From Nature to Market: Examples of Natural Products that Became Drugs
Recent Patents on Biotechnology